Long-Term Effects of Autologous Bone Marrow Stem Cell Treatment in Acute Myocardial Infarction: Factors That May Influence Outcomes by Clifford, DM et al.
Long-term effects of autologous bone marrow stem cell treatment in acute
myocardial infarction: factors that may influence outcomes
Clifford, DM; Fisher, SA; Brunskill, SJ; Doree, C; Mathur, A; Clarke, MJ; Watt, SM; Martin-
Rendon, E
 
 
 
 
 
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/5302
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
Long-Term Effects of Autologous Bone Marrow Stem Cell
Treatment in Acute Myocardial Infarction: Factors That
May Influence Outcomes
David M. Clifford1,2¤, Sheila A. Fisher3, Susan J. Brunskill3, Carolyn Doree3, Anthony Mathur4,6,
Mike J. Clarke5, Suzanne M. Watt1,2, Enca Martin-Rendon1,2*
1 Stem Cell Research Laboratory, NHS-Blood and Transplant, John Radcliffe Hospital, Oxford, United Kingdom, 2Nuffield Department of Clinical Laboratory Sciences,
University of Oxford, Oxford, United Kingdom, 3 Systematic Review Initiative, Clinical Research Group, NHSBT-Oxford, John Radcliffe Hospital, Oxford, United Kingdom,
4Department of Clinical Pharmacology, William Harvey Research Institute, London, United Kingdom, 5All-Ireland Hub For Trials Methodology Research, Queen’s
University, Belfast, United Kingdom, 6 Barts and the London NIHR Biomedical Research Unit, London, United Kingdom
Abstract
Aims: To investigate whether there are important sources of heterogeneity between the findings of different clinical trials
which administer autologous stem cell treatment for acute myocardial infarction (AMI) and to evaluate what factors may
influence the long-term effects of this treatment.
Methods and Results: MEDLINE (1950-January 2011), EMBASE (1974-January 2011), CENTRAL (The Cochrane Library 2011,
Issue 1), CINAHL (1982-January 2011), and ongoing trials registers were searched for randomised trials of bone marrow stem
cells as treatment for AMI. Hand-searching was used to screen recent, relevant conference proceedings (2005–2010/11).
Meta-analyses were conducted using random-effects models and heterogeneity between subgroups was assessed using
chi-squared tests. Planned analyses included length of follow-up, timing of cell infusion and dose, patient selection, small
trial size effect, methodological quality, loss of follow-up and date of publication. Thirty-three trials with a total of 1,765
participants were included. There was no evidence of bias due to publication or time-lag, methodological quality of
included studies, participant drop-out, duration of follow-up or date of the first disclosure of results. However, in long-term
follow-ups the treatment seemed more effective when administered at doses greater than 108 cells and to patients with
more severe heart dysfunction.
Conclusions: Evaluation of heterogeneity between trials has not identified significant sources of bias in this study. However,
clinical differences between trials are likely to exist which should be considered when undertaking future trials.
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Introduction
Although advanced therapies have improved short-term
survival following acute myocardial infarction (AMI), the
incidence of heart failure is steadily increasing worldwide [1].
Current treatments do not address the substantial loss of tissue
through injury nor cell death incurred during AMI [2]. In the
last decade, autologous bone marrow stem cell (BMSC)
treatment has aimed to complement thrombolytic therapies and
primary angioplasty in the treatment of AMI (for review see [3]).
The hypothesis has been that BMSC would improve heart
function delaying the progression of the disease. There is now a
substantial body of evidence from randomised trials to assess the
effects of this treatment, and a recent update of a Cochrane
review by several of the authors of this paper has systematically
reviewed this evidence [4].
The first clinical trials were designed to test the safety and
feasibility of this new treatment, but were not necessarily powered
to assess its efficacy and long-term effects on survival free of major
associated cardiac events [5,6,7,8,9]. To date the treatment
appears safe and associated with low mortality and morbidity
rates (for review see [3,10]). However, there is controversial
evidence that a beneficial effect on global heart function is
significant and persist long-term (for review see [5,11] and
references therein). Clinical evidence from randomised trials of
intracoronary infusion of BMSC post-AMI have been evaluated
previously in several meta-analyses [10,12,13]. The major
limitations in the field that may contribute to these conflicting
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results among trials include the small trial sizes and differences in
patient selection, participants lost to follow-up, cell isolation
protocols, cell dose/type, timing of cell infusion, route of delivery
and methodologies used to measure surrogates; as well as variation
in data acquisition and data analysis protocols. In addition, new
interventions generally raise concerns that early optimism is
fuelled by extreme results in early disclosure just to be contradicted
by later results [14,15,16]. The rationale of the underlying
Cochrane systematic review was to evaluate the efficacy of any
dose of autologous BMSC administered to patients with a
diagnosis of AMI following revascularisation [4]. In our previous
study, sub-group analyses were planned to assess the effect of using
different methods (e.g. magnetic resonance imaging (MRI),
echocardiography, left ventricular angiography, single positron
emission computed tomography (SPECT) or radionucleide ven-
triculography (RNV)) to measure heart function [4]. The aim of
the present study was to conduct further risk of bias and sub-group
analyses to explore whether the overall estimate of treatment effect
size is a reliable guide to its effect and therefore to address some of
the limitations in the field. Here, pre-planned analyses included (i)
small trial size effect, (ii) trial quality and participants lost to follow-
up, (iii) length of follow-up in the trial design, (iv) date of
publication bias, (v) timing of cell infusion, (vi) cell dose/type, (vii)
route of delivery and (viii) differences in patient selection.
Methods
Eligibility
Inclusion criteria: (i) randomized trials, (ii) participants with a
clinical diagnosis of AMI, (iii) within a month of receiving re-
vascularisation by percutaneous coronary intervention (PCI) or
thrombolytic therapy or both, (iv) any dose of autologous BMSC,
(v) any route of administration, (vi) in the comparator arm
participants did not receive BMSC and (vii) any co-interventions
provided they were equally applied to each trial arm.
Search Strategy
The search strategy is detailed elsewhere [4]. Briefly, databases
were searched through to January 31st 2011 for randomised trials
in which BMSC were administered as treatment for AMI,
including MEDLINE (1950–2011), EMBASE (1974–2011), CEN-
TRAL (The Cochrane Library 2011, Issue 1), CINAHL (1982–2011),
PubMed, Lilacs, and the Transfusion Evidence Library. Ongoing
trial registers (ClinicalTrials.gov, the ISRCTN Register and the
WHO International Clinical Trials Platform Registry) were also
searched. Searches were combined with adaptations of the
Cochrane highly sensitive RCT search filter in MEDLINE,
EMBASE and CINAHL [17]. No restrictions by language, year of
publication or publication status were imposed. Proceedings from
the American Heart Association (2005–2010) and International
Society of Stem Cell Research (2005–2011) conferences and the
reference lists of identified studies and relevant review articles were
hand searched for additional studies.
Data Extraction
For each eligible trial, the study and patient population
characteristics, the nature of the intervention and comparator,
and the outcomes assessed were extracted. The quality of the
studies was assessed on the bases of generation of random
sequence, concealment of treatment allocation, blinding of
outcome assessment and adequacy of follow-up [18]. Eligibility
screening, data extraction and assessment of methodological
quality were undertaken independently by a total of three
reviewers, such that at least two reviewers looked at each
potentially eligible trial. Where a trial had used several methods
for outcome assessment (e.g. echocardiography, MRI, SPECT,
RNV or left ventricular angiography), MRI data were preferen-
tially included in our analysis.
Statistical Analysis
Outcome data were analysed quantitatively using RevMan 5
and presented as relative risk (RR) for dichotomous outcomes or
weighted mean difference (WMD) for continuous outcomes with
95% confidence interval (CI), two-sided significance tests are
reported. Meta-analyses were undertaken using random effects
models, due to the high degree of heterogeneity present in these
studies [4,10]. Statistical heterogeneity was examined using the I2
statistic [19] and the chi-squared test.
Sensitivity Analysis
Bias related to study size (such as publication bias [20]) was
assessed by Funnel plots with Egger’s test used to assess
asymmetry. Sensitivity analyses were undertaken for all relevant
included data to assess the influence of (i) the methodological
quality of the trials, (ii) the length of follow-up, (iii) participant
drop-out and (iv) publication date. These analyses were specified
before they were conducted. In the first instance, trials where the
generation of random sequence was rated adequate (marked YES)
were analysed separately from those where the generation of
random sequence was rated as unclear (marked UNCLEAR) or
inadequate (marked NO) as a possible explanation for observed
statistical heterogeneity. To assess the effect of length of follow-up
on results, trials with short term follow-up periods that have been
followed up long term were analyzed separately from those with
no long-term follow-up. The influence of participants drop-out
was determined by analyzing separately trials with less than 20%
drop-out, randomised trials with 20 to 50% drop-out and
randomised trials with greater than 50% drop-out for major
outcomes measured as dichotomous data (e.g. mortality, reinfarc-
tion and target vessel revascularisation). Finally, trials were sub-
grouped on the basis of their by start date, end date, publication of
the main/full article and disclosure or publication of the first
results on the primary outcome (LVEF), to assess the possibility of
a relationship between publication date and effect size. Other
potential reasons for observed heterogeneity were explored via
sub-group analysis, with particular emphasis placed on clinical,
treatment and outcome measurement differences among the
included studies. Sub-groups were stratified by the timing of
BMSC transplantation from onset of AMI, dose of BMSC
administered, route of administration and baseline LVEF.
Differences in effect size between subgroups were assessed using
chi-squared tests for heterogeneity between sub-groups as imple-
mented in RevMan 5.
Results
Description of the Included Studies and Summary of
Previous Findings
The search strategy followed has been described in detail
elsewhere [4]. A total of 2,169 citations were identified in the
initial search of which thirty-three were primary references to
eligible studies (Figure S1). The characteristics of all included
studies are detailed in Tables S1 and S5. The thirty-three included
randomised trials represent thirty-nine treatment comparisons
where BMSC was compared with control in 1,765 patients.
Treatment comparisons were defined following the criteria
previously described (for review see also [4]). Clinical outcomes
and efficacy of BMSC treatment following AMI are fully described
Stem Cell Treatment in Acute Myocardial Infarction
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37373
in detail in our previous study [4] and are summarised here and in
supplementary material for clarity. BMSC administration within a
month of AMI has no significant effect on mortality, morbidity, or
adverse events. Cumulative figures are presented as #61 months
follow-up in supplementary data (Table S2 and reference to
studies in Table S5). The statistical heterogeneity in this case was
negligible (I2 = 0–11%). However, a statistical power calculation
showed that a study with over 5,000 participants in each
randomised group would be required in order to achieve 80%
power to detect any significant difference in mortality rates given
the relatively low incidence of death within the follow-up period
for these trials (2.8% in BMSC and 3.6% in Control groups,
respectively). BMSC treatment significantly improved left ventric-
ular volumes and ejection fraction in short- and long-term follow-
up periods. However, a considerable degree of statistical hetero-
geneity (I2.75%) was observed in both infarct size and LVEF
comparisons. A summary is presented in supplementary data
(Table S3 and reference to studies Table S5). As global LVEF and
infarct size have been used as surrogates in many of the included
trials, this study was design to explore the observed heterogeneity
using these two outcome measures.
Exploring Heterogeneity: Risk of Bias
In order to explore the heterogeneity observed above and to
dispel concerns raised with novel interventions, risks of bias were
assessed according to the criteria described in the Methods.
(a) Risk of publication bias and small study effect. The
possibility of publication bias and study size was assessed by
Funnel plot and the Egger’s test (Figure 1A&B). The analysis
showed no significant small study effects (p = 0.726) and,
therefore, little evidence of publication bias.
(b) Methodological quality of included studies. The
quality assessment of the included studies is summarized in
supplementary data (Table S4). Sensitivity analysis to
estimate the effect of randomization on LVEF was not
required as all included studies followed an adequate method
of sequence generation during randomization (Table S4) and
this could be assessed because of the high quality of reporting
of these relatively recent trials.
(c) Loss of follow-up bias on mortality and morbidity.
In 37 trials, 80% or more (ranging from 80%–100%) of
randomized participants were analyzed by their randomized
treatment group. One trial did not report loss of follow-up
[21]. In the remaining trial, only 63.64% of randomized
participants were included in the analysis [22]. Sensitivity
analyses excluding this trial from the meta-analysis [22] had
a negligible effect on the effects on mortality during short
term (RR 0.80, 95% CI 0.40 to 1.61, p= 0.52 compared to
RR 0.75, 95% CI 0.39 to 1.46, p = 0.40) and long term (RR
0.63, 95% CI 0.20 to 2.00, p= 0.43 compared to RR 0.59,
95% CI 0.22 to 1.56, p = 0.29) follow-up. Similar results
were observed for incidence of re-infarction, restenosis,
hospital readmission and target vessel revascularization,
suggesting a negligible risk of bias. Here the original analyses
with all included studies are presented (Table S2).
(d) Length of follow-up bias on LVEF. For this purpose,
the 36 trials that reported short-term LVEF data were
divided into two groups: 22 trials were followed-up only for
,12 months (Figure 2A) whilst the remaining 14 trials were
followed up for 12–61 months (Figure 2B). BMSC treatment
effect on LVEF in trials followed up for ,12 months (WMD
3.56%, 95% CI 1.74 to 5.37, p = 0.0001- Figure 2A) was not
statistically different from the treatment effect in trials
followed-up for 12–61 months (WMD 2.71%, 95% CI 1.35
to 4.06, p,0.0001- Figure 2B). These results suggest that
those trials with long-term follow-up are representative of all
included studies (Table S1).
(e) Disclosure or publication date bias on LVEF. The
influence of study start date or end date and main
publication date on the primary outcome (LVEF) was
estimated by sorting the included studies according to those
dates. Interestingly, no significant effect was observed in any
of these comparisons, indicating a negligible risk of bias on
treatment effect. However, when trials were grouped by the
year when the first results were disclosed, the studies that
disclosed their results first (in 2004) [6,23] showed an
average greater effect on LVEF in favour of the treatment
than the studies that were designed or reported later
(Figure 3A). If we exclude these early trials from the meta-
analysis, the overall estimate for the effect on LVEF was
reduced (WMD 2.80%, 95% CI 1.83 to 3.77, p,0.001-
Figure 3B) compared to the pool of all included studies
(WMD 3.26%, 95% CI 2.12 to 4.40, p,0.001- Figure 3A).
However, the difference was not substantial and the
inclusion of trials with the early, most promising results
showed low risk of bias.
Exploring Heterogeneity: Sub-group Analysis
Planned sub-group analyses were carried out to assess the
impact of (i) the timing of the BMSC transplantation following
AMI, (ii) the dose of BMSC administered, (iii) the route of
administration and (vi) the baseline LVEF on infarct size and
LVEF for long term follow-up (Table 1). Timing of administration
of BMSC infusion was sub-grouped into #7days and .7days, to
reflect the median delay to BMSC infusion from AMI across
included studies. Our previous work suggested that doses of
BMSC .108 would be required to observe a significant change in
LVEF in the treated arm compared with the control arm [10].
Therefore, for the purpose of this study, trials were divided into
two groups according to dose: #108 BMSC and .108 BMSC. All
included trials where the route of administration is detailed in their
methods administered BMSC via the infarct related coronary
artery. Only one trial compared venus and arterial delivery of
BMSC [24]. Therefore, the pre-planned analysis subgrouping the
trials by route of delivery was deemed not appropriate in the
present study. Finally, further analyses were carried out dividing
the trials in two groups to reflect the median value of baseline
LVEF in the included trials: #40% and .40% baseline LVEF.
(a) Timing of BMSC infusion. Table 1 shows statistically
significant changes in both infarct size (WMD=25.2%,
p= 0.007) and LVEF (WMD=4.8%, p= 0.0003), in favour
of BMSC, when the treatment was administered within
7 days post-AMI. At present, there are no data available to
assess the long term effect on BMSC on infarct size for
treatment administered after 7 days, however a significant
difference in LVEF in favour of BMSC was maintained
when the treatment was administered later than 7 days
(WMD=5.9%, p= 0.01). No significant differences between
subgroups were observed for long-term follow-up LVEF
(p = 0.68).
(b) BMSC dose. BMSC treatment had a significant effect on
infarct size (WMD=24.3%, p = 0.005) and LVEF
(WMD=4.7%, p= 0.0001) after long-term follow-up when
doses .108 BMSC were administered. In contrast, the
Stem Cell Treatment in Acute Myocardial Infarction
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infarct size and LVEF showed no significant improvement
when doses #108 BMSC were administered.
(c) Baseline LVEF. Furthermore, the long-term reduction in
infarct size in favour of BMSC treatment was statistically
significant when the treatment was administered to partic-
ipants with baseline LVEF #40% (WMD=25.1%,
p= 0.006) whereas no significant effect was observed in
participants with baseline LVEF .40% (WMD=21.4%,
p = 0.23). The difference in effect sizes these between
subgroups was marginally significant (p = 0.08). The effect
of BMSC on LVEF was also greater and more statistically
significant when participants had LVEF #40% at baseline
(WMD=5.6%, p,0.0001) compared with participants with
baseline LVEF .40% (WMD=2.4%, p = 0.006), the
difference in effect size between these subgroups was clearly
significant for this outcome (p = 0.04).
Taken together, these data indicate that the timing of BMSC
transplantation following AMI, the dose of BMSC administered and
the baseline LVEF are factors that may contribute to the clinical hete-
rogeneity observed among the studies included in this meta-analysis.
Discussion
The present study was designed: (i) to assess potential risks of bias
and diversity amongst different randomised trials to address major
limitations in the field and (ii) to evaluate what factorsmay influence the
long-term effect of BMSC treatment. This meta-analysis confirms the
findings of our previous study [4] that BMSC treatment moderately
improves heart function and has as yet not been associated with any
significant safety concerns, but does not decrease mortality or
morbidity significantly in long-term follow-up (with the caveat that
there have been no studies designed to address mortality). Our power
Figure 1. Assessment of risk of bias due to publication and study size on LVEF. (A) Funnel plot and (B) Egger’s test. No significant risk of
publication bias or small study effects was observed.
doi:10.1371/journal.pone.0037373.g001
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Figure 2. Forest plot of Weighted Mean Difference [WMD, with 95% CI (confidence interval)] in left ventricular ejection fraction
(LVEF) in short-term follow-up. (A) Twenty-two randomised trials reporting only short-term follow-up and (B) the remaining 14 trials that
reported long-term outcome data as well as short-term data. BMSC treatment significantly improved LVEF in trials with short-term follow-up (3.56%,
95% CI 1.74 to 5.37, p,0.0001) as well as in trials with short- and long-term follow-up (2.71%, 95% CI 1.35 to 4.06, p,0.0001).
doi:10.1371/journal.pone.0037373.g002
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calculation estimates that a trial with several thousand participants
would be needed to detect significant differences in mortality between
treatment and control groups. Recently, the first trial to address
mortality associated with BMSC treatment in patients who suffered
AMI has been designed and funded by the EuropeanUnion (EU FP7–
BAMI). The BAMI trial will be administering unfractionated bone
marrow mononuclear cells to patients who have suffered from AMI,
similarly to the majority of trials included in the present study. The
results of this trial should allow us to directly answer the question of
whether BMSC therapy following AMI can change the prognosis of
this disease.
As the results of the present study are not always consistent with
those of large randomised trials [7,8,25,26,27], we have conducted
extensive sensitivity analyses to evaluate potential factors that may
account for the discrepancies observed. Major limitations in the
field have been enumerated earlier in the Introduction. Impor-
tantly, the underlying Cochrane systematic review for this study is
unique and superior to others previously reported in a number of
ways and has allowed us to address some of those issues. Firstly, it
is based on a comprehensive search strategy and a protocol
approved by the Cochrane Collaboration prior to starting the
search. Although the majority of randomised trials were identified
through searching the main databases (MEDLINE, EMBASE,
CENTRAL and CINAHL), hand-searching identified several
crucial references used to assess risk of bias that would have
otherwise been missed [7,21,26,28,29,30,31]. Secondly, the
robustness of the original systematic review has been tested
extensively within this study through a comprehensive sensitivity
analysis and risk of bias assessment to explore the presence and
impact of heterogeneity. Finally, the large number of trials
included here allows particularly powerful assessments of hetero-
geneity through planned sub-group analysis.
It has been suggested that measurement of surrogates such as
LVEF by different methodology may be a risk of bias because of
the known limitations of some methods [32]. Analysis of the
included studies sub-grouped by the methodology used to measure
surrogate outcomes has been addressed elsewhere [4]. It has also
been suggested that stopping or reporting early results in
randomised trial may affect the perception that the public has of
the treatment efficacy in novel interventions [33]. As early results
are more limited than the results of a final analysis, concerns have
been raised as treatment effects seen early may either not be real
or may be overly optimistic. In this study, we have had a unique
opportunity to assess whether factors such as short versus long
follow-up or early reporting of results may contribute to bias
amongst the pooled results of all included trials. The risk of bias
due to length of follow-up for LVEF was negligible indicating that
those trials with long term follow-up data are representative of all
included studies. This conclusion may have implications inter-
preting early results from trials with long-term follow-up or trials
with short term follow-up only. In addition, low risk of bias was
observed when studies were grouped by study start date, study end
date or publication of main reference to the studies. There were no
significant differences of treatment effect on LVEF when two early
Figure 3. Forest plot of Weighted Mean Difference [WMD, with
95% CI (confidence interval)] in left ventricular ejection
fraction (LVEF) in short-term follow-up sub-grouped by the
year of the first results’ disclosure. (A) Including early studies
reporting data in 2004 (3.26%, 95% CI 2.12 to 4.40, p,0.00001).and (B)
excluding studies with early reporting in 2004 (2.80%, 95% CI 1.83 to
3.77, p,0.00001). BMSC treatment significantly improved LVEF in both
meta-analyses. WMD had overlapping CI and were not significantly
different.
doi:10.1371/journal.pone.0037373.g003
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studies [5,6] where either included or excluded from the meta-
analysis and negligible risk of bias due to quality of included
studies or loss of participant’s follow-up. This may also imply that
trial design and methodology has not changed drastically amongst
trials in the last decade for significant differences to be observed.
Although no significant risk of bias was observed in the present
study, one cannot exclude the possibility that discrepancies
between the different studies may be explained by variability in
factors such as cell isolation, data acquisition or data analysis
protocols amongst others. Hence the importance of agreeing to
standardised protocols in the future. Part of the remit of the BAMI
trial (EU-BAMI mentioned above) is to consider the methodolo-
gies used to date and produce a standardised technique for bone
marrow processing and delivery.
Here, a parallel significant improvement on LVEF and
reduction of infarct size was observed. Although caution is
advisable in interpreting results from surrogate outcomes, the
moderate improvement in LVEF over short- (3.26%) and long-
term (3.91%) follow-up is similar to that obtained in previous
trials where AMI patients were treated with a combination of
thrombolytic therapy and PCI [34,35]. In the CADILLAC trial,
improvement of LVEF correlated with better long-term survival
rate [35,36]. The results of the CADILLAC trial were also
consistent with those of the Netherland’s trial, where thrombo-
lytic therapy was administered to patients suffering from AMI
[37]. Consequently, the moderate but significant improvement in
LVEF in favour of BMSC treatment reported in the present
study could be clinically very relevant providing that limitations
such as study size could be overcome. Improvement in long-term
survival has been suggested by the results of two recent
randomised trials [28,38]. When sub-group analyses were
conducted, greater effects on infarct size were observed when
BMSC were administered earlier (#7days). Effects on both
infarct size and LVEF were greater when BMSC were
administered at doses .108 and to patients with larger infarcts
or lower baseline LVEF. This is in agreement with previous
published results [10,39]. Administering cells earlier may reduce
infarct size and reduce damage during ventricular remodelling
thus preventing or delaying the onset of heart failure. The
requirement for a larger dose of BMSC to reduce infarct size and
improve LVEF can be explained by the low rates of cell
retention in the heart after BMSC infusion [29,40]. This
supports the idea that the treatment may have a paracrine effect
[41]. A number of randomised trials are currently addressing the
effects of timing of stem cell transplantation [42,43], cell dose
[44,45,46], cell delivery [24] and cell composition [27] on global
left ventricular function. Although global LVEF has been a
primary surrogate measured in the majority of included trials, the
results presented here should be carefully considered, as there is
still no evidence of clinical efficacy.
In summary, we have addressed some of the limitations present in
the field here and elsewhere [4]. However, other limitations such as
small study sizes, patient-related factors and variability in protocols
still remain. This study shows that risk of bias due to publication,
quality of the studies, loss of follow-up, duration of follow-up and
date of disclosure of early results is minor among randomised trials
that administer BMSC as treatment for AMI. BMSC treatment
significantly reduces infarct size and improves LVEF long-term.
Factors such as timing of BMSC transplantation, cell dose and
baseline LVEF could affect the successful outcome of this treatment.
An attempt has now been made with the design of the BAMI trial to
standardise the techniques of BMNC isolation and delivery to man
and to measure clinically significant end-points such as mortality.T
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